Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:52.707Z.
Calculation as of: 2026-10-06T16:57:52.707Z.
Quote observation: 2026-10-06T16:55:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a0cb01cc31f7f7a1ab27ea5f4e27b2bab80fdffd2dde3b1d08905865647984d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Paranovus Entertainment Technology Ltd.
Market Cap
$3.23M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Paranovus Entertainment Technology Ltd. (PAVS) | $3.23M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.27M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.23M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.18M | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $3.12M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.13M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.40M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.42M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.00M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
